PBC, or primary biliary cholangitis, is a chronic autoimmune liver disease in which the body’s immune system slowly destroys the small bile ducts inside the liver. These ducts normally carry bile, a digestive fluid, out of the liver and into the intestine. When they’re damaged, bile builds up in the liver, causing inflammation and, over time, scarring that can progress to serious liver damage. PBC predominantly affects women, who account for roughly 70% of cases, with female-to-male ratios ranging from about 2:1 to 4:1 depending on the population studied.
How PBC Damages the Liver
In a healthy liver, bile flows through a network of tiny ducts lined by specialized cells called biliary epithelial cells. These cells protect themselves from the corrosive effects of bile acids by secreting bicarbonate, which creates an alkaline shield on their surface. In PBC, two things go wrong simultaneously.
First, immune cells, particularly a type of white blood cell called T lymphocytes, mistakenly identify the lining of these bile ducts as a threat. They swarm around the ducts alongside other immune cells and release substances that kill the duct-lining cells. Second, the protective bicarbonate shield breaks down. Without that alkaline buffer, bile acids penetrate the duct-lining cells and trigger further cell death from the inside. The combination of immune attack from outside and bile acid damage from within leads to progressive duct destruction.
As ducts disappear, bile has nowhere to go. It pools in the liver, a condition called cholestasis. The trapped bile acids are toxic to liver tissue, and over years to decades, this ongoing injury can cause fibrosis (scarring) that may eventually progress to cirrhosis.
Common Symptoms
Many people with PBC have no symptoms at all when they’re first diagnosed, with the disease detected through routine blood work showing elevated liver enzymes. When symptoms do appear, the two most common are fatigue and intense itching.
The fatigue in PBC isn’t ordinary tiredness. It has both a mental and physical dimension. On the mental side, people describe difficulty with concentration and memory, along with a deep lack of motivation often characterized as “the failure to initiate activities requiring self-motivation.” The physical side involves a reduced capacity for sustained effort. Researchers believe this fatigue stems from toxic bile acids leaking into the bloodstream and triggering widespread inflammation that ultimately affects brain function. Sleep disturbance and depression frequently accompany it.
The itching, or pruritus, can be severe and relentless. When bile flow is impaired, compounds that would normally be excreted through bile escape into the bloodstream and eventually reach the skin. There, they stimulate nerve fibers that send itch signals to the brain. The itching tends to be worse at night and can significantly disrupt sleep and quality of life. Bile acids, certain fat-derived molecules, and the body’s own opioid-like chemicals have all been identified as potential itch triggers in PBC.
Other symptoms that may develop over time include dry eyes and dry mouth, darkening of the skin, and small fatty deposits under the skin around the eyes.
How PBC Is Diagnosed
Diagnosis typically relies on two out of three criteria: blood tests showing cholestasis (specifically, elevated alkaline phosphatase, a liver enzyme that rises when bile flow is impaired), the presence of a specific autoantibody called anti-mitochondrial antibody (AMA), and characteristic findings on a liver biopsy.
AMA is the hallmark blood test for PBC. A large meta-analysis found it has a sensitivity of about 84% and a specificity of 98%, meaning it correctly identifies most people with the disease while very rarely producing a false positive. A more targeted version of this test, the M2 subtype, performs even better, with sensitivity around 89%. In practice, if you have elevated alkaline phosphatase and a positive AMA test, the diagnosis is considered established without needing a biopsy.
A liver biopsy becomes necessary only when blood tests and imaging don’t provide a clear answer. When it is performed, the classic finding is immune cells clustered around damaged bile ducts. Biopsy can also help determine how far the disease has progressed, which is useful for predicting long-term outcomes.
Conditions That Often Accompany PBC
Because PBC is autoimmune in nature, it frequently overlaps with other autoimmune conditions. About one-third of people with PBC have at least one additional autoimmune disease. The most common companion is Sjögren’s syndrome, which causes dry eyes and dry mouth. In fact, symptoms of Sjögren’s appear in 47% to 73% of PBC patients. Other frequently associated conditions include autoimmune thyroid disease, Raynaud’s phenomenon (where fingers turn white or blue in response to cold), scleroderma, and systemic lupus.
Bone loss is another significant concern. Roughly 30% of PBC patients develop osteoporosis, and that figure climbs to 44% among those with advanced liver disease. Experts recommend bone density testing at the time of PBC diagnosis. If results are normal, repeat testing every two to three years is typical, while those with additional risk factors for bone loss (such as long-term steroid use, low body weight, early menopause, or smoking) should be tested annually.
First-Line Treatment With UDCA
The cornerstone of PBC treatment is ursodeoxycholic acid (UDCA), a medication taken daily by mouth. UDCA is a naturally occurring bile acid that helps improve bile flow and protects liver cells from damage caused by more toxic bile acids. The standard dose is 13 to 15 milligrams per kilogram of body weight per day.
UDCA doesn’t cure PBC, but it substantially slows disease progression. In a landmark trial published in the New England Journal of Medicine, patients treated with UDCA had a 68% lower risk of needing a liver transplant compared to those on placebo, and a significantly lower combined risk of transplant or death. For people who respond well to UDCA, life expectancy can approach that of the general population. The medication is generally well tolerated, and most patients remain on it indefinitely.
However, not everyone responds adequately. About 30% to 40% of patients continue to show signs of active disease despite taking UDCA consistently. These patients need additional treatment.
Newer Options for Incomplete Responders
For people whose disease isn’t fully controlled by UDCA alone, newer second-line medications have become available. Obeticholic acid was conditionally approved in 2016. It works by activating a receptor in the liver that helps regulate bile acid production. In clinical trials, about 37% of patients who hadn’t responded to UDCA showed improvement with obeticholic acid. The main drawback is itching: roughly 40% of patients experience worsened pruritus, and it’s the leading reason people stop taking the drug, accounting for nearly half of all discontinuations.
More recently, seladelpar received accelerated FDA approval after promising clinical trial results. It belongs to a newer class of drugs that work by activating a receptor involved in bile acid transport and cholesterol metabolism. Beyond improving bile flow, seladelpar also appears to have anti-inflammatory and anti-scarring effects in the liver. Another drug in this class, elafibranor, has shown the highest efficacy at improving alkaline phosphatase levels among second-line therapies in comparative analyses. These newer options represent a meaningful expansion of the treatment toolkit for PBC patients who don’t respond to UDCA alone.
Long-Term Outlook
PBC is a disease measured in decades, not months. Many people diagnosed early and treated effectively with UDCA live full lives without ever developing cirrhosis. The key factor in long-term prognosis is how well your liver enzymes respond to treatment, particularly whether alkaline phosphatase levels drop toward normal and whether other markers like bilirubin remain stable.
For those whose disease does progress to advanced cirrhosis, liver transplantation is an effective option with excellent outcomes. PBC can recur in the transplanted liver, but this typically happens slowly and rarely leads to graft failure.
Regular monitoring is central to managing PBC well. This includes periodic blood tests to track liver function, bone density screening, and assessment for associated autoimmune conditions. Because the disease progresses silently in many cases, consistent follow-up matters even when you feel fine.